Inhibition of Amyloid Beta Aggregation and Deposition of Cistanche tubulosa Aqueous Extract

12Citations
Citations of this article
20Readers
Mendeley users who have this article in their library.

Abstract

Cistanche tubulosa aqueous extract (CTE) is already used as a botanical prescription drug for treating dementia in China. Our previous studies reported that phenylethanoid glycosides of CTE have anti-Alzheimer’s disease (AD) activity by inhibiting amyloid β peptide (Aβ) aggregation and deposition. However, recent studies considered that the phenylethanoid glycosides may be metabolized by intestinal bacteria, because all analysis results showed that the bioavailability of phenylethanoid glycosides is extremely low. In this study we demonstrate how iron chelation plays a crucial role in the Aβ aggregation and deposition inhibition mechanism of phenylethanoid glycosides of CTE. In addition, we further proved phenylethanoid glycosides (1–3) could reach brain. Active CTE component and action mechanism confirmation will be a great help for product quality control and bioavailability studies in the future. At the same time, we provide a new analysis method useful in determining phenylethanoid glycosides (1–3) in plants, foods, blood, and tissues for chemical fingerprint and pharmacokinetic research.

Cite

CITATION STYLE

APA

Chao, C. L., Huang, H. W., Huang, H. C., Chao, H. F., Yu, S. W., Su, M. H., … Lin, H. C. (2019). Inhibition of Amyloid Beta Aggregation and Deposition of Cistanche tubulosa Aqueous Extract. Molecules, 24(4). https://doi.org/10.3390/molecules24040687

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free